Trial Profile
A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; TRX 518 (Primary)
- Indications Advanced breast cancer; Appendiceal cancer; Biliary cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors GITR Inc; Leap Therapeutics
- 02 May 2022 Results published in the Clinical Cancer Research
- 23 Oct 2020 Status changed from active, no longer recruiting to completed.
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.